Page tree




Date

20210421

Document Version

1.0

Release Status

PRODUCTION

  

© 2024 International Health Terminology Standards Development Organisation.  All rights reserved.  SNOMED CT® was originally created by the College of American Pathologists.

This document forms part of the SNOMED CT® Ireland Extension release distributed by International Health Terminology Standards Development Organisation, trading as SNOMED International, and is subject to the SNOMED CT® Affiliate License, details of which may be found at https://www.snomed.org/snomed-ct/get-snomed

No part of this document may be reproduced or transmitted in any form or by any means, or stored in any kind of retrieval system, except by an Affiliate of SNOMED International in accordance with the SNOMED CT® Affiliate License. Any modification of this document (including without limitation the removal or modification of this notice) is prohibited without the express written permission of SNOMED International.

Any copy of this document that is not obtained directly from SNOMED International [or a Member of SNOMED International] is not controlled by SNOMED International, and may have been modified and may be out of date. Any recipient of this document who has received it by other means is encouraged to obtain a copy directly from SNOMED International [or a Member of SNOMED International. Details of the Members of SNOMED International may be found at http://www.snomed.org/members/].







Page At A Glance


1. Introduction

SNOMED CT terminology provides a common language that enables a consistent way of indexing, storing, retrieving, and aggregating clinical data across specialties and sites of care.

The International Health Terminology Standards Development organisation (IHTSDO®), trading as SNOMED International, maintains the SNOMED CT technical design, the content architecture, the SNOMED CT content (includes the concepts table, the descriptions table, the relationships table, a history table, and ICD mappings), and related technical documentation.

The SNOMED CT Irish Extension - packages these components for release every April and October, to be used with the latest SNOMED CT International Edition release.

The same content can be viewed online using the SNOMED CT browser., and eHealth Ireland  website

2. Background

This document provides a summarized description of the content changes included in the April 2021 Production release of the SNOMED Clinical Terms® Managed Service Ireland Extension package.

It will also include technical notes detailing the known issues which have been identified (should any of these exist). These are content or technical issues where the root cause is understood, and the fix has been discussed and agreed, but has yet to be implemented.

This Ireland Extension package is dependent upon, and should therefore be consumed in conjunction with the SNOMED CT® January 2021 International Edition release.

2.1. Scope

This document is written for the purpose described above and is not intended to provide details of the technical specifications for SNOMED CT or encompass every change made during the release.


3. Content Development Activity

3.1. Summary

Content from the SNOMED CT® January 2021 International Edition release has been included, alongside additional components for use in Ireland. 

This extension contains concepts, relationships and reference sets for healthcare professionals. 

3.2. New and Updated Content

3.2.1. New content in this release:

This is the 4th SNOMED CT Irish Edition Production release.

3.2.2. New and updated content

3.2.2.1. Concept statistics

The SNOMED Irish National Release Center published 61 new concepts and these are available in the Irish Extension April release.

Table 1. New concepts in the Irish Edition April release

Total number of concepts

61

Qualifier Value

16

Procedure (procedure)

3

Observable entity(observable entity)

21

Record artifact

0

Regime Therapy

0

Ethnic group

0

Environment9
Finding

5

Foundation Metadata Concept1
Medicinal Products3
Occupation3
Component Type New Count
Axioms61
Concepts61
Descriptions - en154
Language Refsets - en218
Relationships75

 Refer to Appendix 1, Table 1.1 to view the 61 new concepts.

 This content was derived through the dataset specification process (DSMP) and other projects such as the Covid Immunisation Project and includes concepts from

  • eServices
  • Safeguarding Ireland
  • Make Every Contact Count (MECC)
  • Ireland Nursing Midwifery Quality Care Metrics

3.2.2.2. Reference sets

There a 4 new reference sets in this release

  • eServices
  • Safeguarding Ireland
  • Make Every Contact Count (MECC)
  • Ireland Nursing Midwifery Quality Care Metrics

3.2.2.3.  New concepts promoted via Content Request Service


Total number of concepts promoted October 2020 release 24
Clinical drugs24


Total number of concepts promoted April 2021 release       90
Clinical drugs76
Finding10
Situation4


Refer to Appendix 2 Table 2.2 to view these concepts


4. Technical notes

4.1. Known Issues

Known Issues are content or technical issues where the root cause is understood, and the resolution has been discussed and agreed but has yet to be implemented.  This can be due to a number of reasons, from lack of capacity within the current editing cycle, to the risk of impact to the stability of SNOMED CT if the fix were to be deployed at that stage in the Product lifecycle.  

For the SNOMED CT Managed Service - Ireland Extension Release, the following Known Issues were identified, and agreed to be resolved in the next editing cycle:

Key Summary Description P
Loading...
Refresh

4.2. Resolved Issues

Resolved Issues are those where the resolution has been discussed and agreed, and has been implemented in time for this release. 

For the SNOMED CT Managed Service - Ireland Extension Release, the following Issues were Resolved:

Key Summary Description P
Loading...
Refresh

4.3. Technical notes

No additional technical notes for this release.



 

5. Appendix 1


5.1. Table 1.1

Id FSN Semantic Tag
941000220103South/South West Hospital Group (environment)(environment)
911000220102Royal College of Surgeons of Ireland Hospital Group (environment)(environment)
951000220101Childrens Health Ireland (environment)(environment)
891000220104Irish Hospital groups (environment)(environment)
921000220109Dublin Midlands Hospital Group (environment)(environment)
961000220104Ireland East Hospital Group (environment)(environment)
931000220107University Limerick Hospital Group (environment)(environment)
901000220100Saolta Hospital Group (environment)(environment)
871000220100Health Service Executive hospital (environment)(environment)
1481000220100Ex-smoker for more than 6 months (finding)(finding)
1321000220109Consent given for 2nd dose severe acute respiratory syndrome coronavirus 2 vaccination (finding)(finding)
1391000220106Meets eligibility criteria for severe acute respiratory syndrome coronavirus 2 vaccination (finding)(finding)
1491000220102Ex-smoker for less than 6 months (finding)(finding)
1311000220102Consent given for 1st dose severe acute respiratory syndrome coronavirus 2 vaccination (finding)(finding)
1451000220107Make Every Contact Count reference set Ireland (foundation metadata concept)(foundation metadata concept)
1411000220106COVID-19 mRNA Vaccine Pfizer-BioNTech 30 micrograms per 0.3ml dose concentrate for suspension for injection multidose vials (medicinal product)(medicinal product)
1421000220104COVID-19 mRNA Vaccine Moderna 0.1mg per 0.5mL dose dispersion for injection multidose vials (medicinal product)(medicinal product)
1401000220108COVID-19 Vaccine AstraZeneca 5 x10,000,000,000 viral particles per 0.5ml dose for injection multidose vials (medicinal product)(medicinal product)
1251000220106Manager email address (observable entity)(observable entity)
971000220105Postal code (observable entity)(observable entity)
1191000220109Place of residence (observable entity)(observable entity)
1351000220101Staff identification (observable entity)(observable entity)
1291000220101Service user email address (observable entity)(observable entity)
1161000220102Service user forename (observable entity)(observable entity)
981000220108General Practioner address (observable entity)(observable entity)
1361000220104Vaccinator surname (observable entity)(observable entity)
1171000220108Service user surname (observable entity)(observable entity)
1331000220107Service user home telephone number (observable entity)(observable entity)
1201000220107Postal address (observable entity)(observable entity)
1271000220102Registration number (observable entity)(observable entity)
861000220106Individual health identifier (observable entity)(observable entity)
1301000220100Service user address (observable entity)(observable entity)
1241000220109Date of verification of registration (observable entity)(observable entity)
1341000220103General medical services number (observable entity)(observable entity)
1181000220106Healthcare facility identification (observable entity)(observable entity)
1211000220105Work address (observable entity)(observable entity)
1281000220104Service users mobile telephone number (observable entity)(observable entity)
1151000220104Personal public health number (observable entity)(observable entity)
1381000220108Vaccinator forename (observable entity)(observable entity)
1221000220103Perscriber (occupation)(occupation)
1261000220108Job title occupation (occupation)(occupation)
1231000220100Vaccinator (occupation)(occupation)
1431000220101Administration of first dose of severe acute respiratory syndrome coronavirus 2 vaccine (procedure)(procedure)
1371000220105Polymerase chain reaction test for Severe acute respiratory syndrome coronavirus 2 (procedure)(procedure)
1441000220105Administration of second dose of severe acute respiratory syndrome coronavirus 2 vaccine (procedure)(procedure)
1061000220101Health promotion and improvement service (qualifier value)(qualifier value)
881000220102Child and family agency (qualifier value)(qualifier value)
1031000220109Office of Chief Information Officer (qualifier value)(qualifier value)
1131000220105General support staff service (qualifier value)(qualifier value)
1001000220102Community voluntary agency section 38 (qualifier value)(qualifier value)
1071000220107Health business services (qualifier value)(qualifier value)
1101000220103Business Relationship Management service (qualifier value)(qualifier value)
1041000220100Human resource services (qualifier value)(qualifier value)
1141000220101Patient client care staff (qualifier value)(qualifier value)
1011000220104Health Service Executive (qualifier value)(qualifier value)
1081000220105Environmental health service (qualifier value)(qualifier value)
991000220106Community voluntary agency section 39 (qualifier value)(qualifier value)
1051000220103Health and wellbeing service (qualifier value)(qualifier value)
1501000220109Smoking cessation service (qualifier value)(qualifier value)
1021000220106Finance service (qualifier value)(qualifier value)
1091000220108Procurement service (qualifier value)(qualifier value)

6. Appendix 2


July 2020 International  Release and October 2020 Irish Edition ReleaseDate of submission to CRS
Product containing precisely midostaurin 25 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely nintedanib (as esilate) 150 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely nintedanib (as esilate) 100 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely glucosamine (as glucosamine sulfate potassium chloride) 400 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely lomitapide (as mesilate) 10 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely lomitapide (as mesilate) 20 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely lomitapide (as mesilate) 5 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely cabozantinib (as cabozantinib S-malate) 20 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely cabozantinib (as cabozantinib S-malate) 80 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely ibrutinib 140 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely nitisinone 20 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely panobinostat (as lactate) 10 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely panobinostat (as lactate) 15 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely panobinostat (as lactate) 20 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely isavuconazole (as isavuconazonium sulfate) 200 milligram powder for concentrate for solution for infusion12/03/2020
Product containing precisely eliglustat (as tartrate) 84 milligram/1 each conventional release oral capsule12/03/2020
Product containing precisely palbociclib 75 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely palbociclib 100 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely palbociclib 125 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely ixazomib (as citrate) 2.3 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely ixazomib (as citrate) 3 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely ixazomib (as citrate) 4 milligram/1 each conventional release oral capsule (clinical drug)12/03/2020
Product containing precisely precisely silver sulfadiazine 1 milligram/1 each conventional release cutaneous cream (clinical drug)12/03/2020
Product containing precisely minoxidil 50 milligram/1 milliliter conventional release cutaneous solution (clinical drug


Jan 2021 International  Release and April 2021 Irish Edition ReleaseDate of submission to CRS
Product containing precisely misoprostol 400 microgram/1 each conventional release oral tablet (clinical drug)01/07/2020
Product containing precisely mifepristone 600 milligram/1 each conventional release oral tablet (clinical drug)01/07/2020
Product containing precisely tocilizumab 20 milligram/1 milliliter conventional release solution for injection (clinical drug)01/07/2020
Product containing trastuzumab emtansine (medicinal product)
Product containing precisely metoprolol tartrate 1 mg/1 ml conventional release solution for injection (clinical drug)20/07/2020
Product containing precisely perindopril arginine 5 mg/1 each conventional release oral tablet (clinical drug)20/07/2020
Product containing precisely prednisolone (as prednisolone metasulphobenzoate sodium) 20 mg/1 actuation conventional release rectal foam (clinical drug)20/07/2020
Product containing precisely paracetamol 500 mg/1 each tablet for conventional release oral solution (clinical drug)20/07/2020
Product containing precisely epinephrine 500 mcg/1 ml conventional release solution for injection (clinical drug)20/07/2020
Product containing precisely atropine sulfate 200 mcg/1 ml conventional release solution for injection (clinical drug)20/07/2020
Product containing precisely acetylcysteine 600 mg/1 each conventional release effervescent oral tablet (clinical drug)20/07/2020
Product containing precisely mepolizumab 100 mg/1 each powder for conventional release solution for injection (clinical drug)
Product containing precisely levocarnitine 300mg/ml conventional release oral solution (clinical drug)20/07/2020
Product containing precisely cyanocobalamin 500 mcg/1 each conventional release oral tablet (clinical drug)20/07/2020
Product containing precisely nicotinic acid 500 mg/1 each capsule (clinical drug)20/07/2020
Product containing precisely aprepitant 40 mg/1 each conventional release oral capsule (clinical drug)
Product containing precisely tetracaine hydrochloride 10 milligram/1 milliliter conventional release eye drop solution (clinical drug)27/07/2020
Product containing precisely tetracaine hydrochloride 5 milligram/1 milliliter conventional release eye drop solution (clinical drug)27/07/2020
Product containing precisely oxybuprocaine hydrochloride 0.4 mg/1 ml conventional release eye drop solution (clinical drug)27/07/2020
Product containing precisely benzyl benzoate 25% conventional release cutaneous emulsion (clinical drug)27/07/2020
Product containing precisely betamethasone (as betamethasone valerate) 1 mg/1 ml conventional release cutaneous solution (clinical drug)27/07/2020
Product containing precisely propamidine isetionate 1 milligram/1 milliliter conventional release eye drop solution (clinical drug)27/07/2020
Product containing precisely calcium polystyrene sulfonate 99.934% powder for oral or rectal suspension (clinical drug)
Product containing precisely calcium undecylenate 10% conventional release cutaneous powder (clinical drug)27/07/2020
Product containing precisely miconazole 20 milligram /1 g conventional release oral gel (clinical drug)27/07/2020
Product containing precisely ferrous sulfate 325 mg/1 each prolonged-release oral tablet (clinical drug)27/07/2020
Product containing precisely fluorescein sodium 20 milligram/1 millilitre conventional release eye drop solution (clinical drug)27/07/2020
Product containing precisely soya oil 100 gram /1 litre conventional release emulsion for infusion (clinical drug)27/07/2020
Product containing precisely soya oil 200 gram /1 litre conventional release emulsion for infusion (clinical drug)27/07/2020
Product containing precisely potassium chloride 375 milligram /5 millilitre conventional release oral solution (clinical drug)27/07/2020
Product containing precisely afatinib (as afatinib dimaleate) 50 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely agomelatine 25 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely agomelatine (as agomelatine citric acid) 25 milligram/1 each conventional release oral tablet (clinical drug
Product containing precisely avatrombopag (as avatrombopag maleate) 20 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely azilsartan medoxomil (as azilsartan medoxomil potassium) 20 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely baricitinib 2 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely baricitinib 4 milligram /1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely bazedoxifene (as bazedoxifene acetate) 20 milligram /1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely bilastine 20 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely bilastine 2.5 mg/1 ml conventional release oral solution (clinical drug)27/07/2020
Product containing precisely bilastine 10 mg/1 each conventional release orodispersible tablet (clinical drug)27/07/2020
Product containing precisely binimetinib 15 mg/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brigatinib 30 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely brigatinib 90 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brigatinib 180 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brivaracetam 100 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brivaracetam 10 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brivaracetam 25 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brivaracetam 50 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely brivaracetam 75 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely cabozantinib (as cabozantinib s-malate) 20 milligram/1 each conventional release oral tablet27/07/2020
Product containing precisely cabozantinib (as cabozantinib s-malate) 40 milligram/1 each conventional release oral tablet27/07/2020
Product containing precisely cabozantinib (as cabozantinib s-malate) 60 milligram/1 each conventional release oral table
Product containing precisely calcium acetate 500 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely capecitabine 300 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely clotrimazole 500 milligram/1 each conventional release pessary (clinical drug)27/07/2020
Product containing precisely clotrimazole 200 milligram/1 each conventional release pessary (clinical drug)27/07/2020
Product containing precisely desmopressin acetate 100 microgram/1 millilitre conventional release nasal drops, solution (clinical drug)27/07/2020
Product containing precisely wool alcohols 2 milligram/1 gram conventional release eye ointment (clinical drug)27/07/2020
Product containing precisely hydroxocobalamin (as hydroxocobalamin chloride) 1000 microgram/1 millilitre conventional release solution for injection (clinical drug)27/07/2020
Product containing precisely dihydrocodeine tartrate 2.42milligram/1 millilitre conventional release oral solution (clinical drug)27/07/2020
Product containing precisely dihydrocodeine tartrate 10 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely pilocarpine nitrate 20 milligram/1 millilitre conventional release eye drops, solution (clinical drug)
Product containing precisely prednisolone acetate 1.2 milligram/1 millilitre each conventional release eye drops, suspension (clinical drug)27/07/2020
Product containing precisely calcium carbonate 90 grams/ 100 grams conventional release cutaneous powder (clinical drug)27/07/2020
Product containing precisely cinnarizine 25 milligram/1 each conventional release oral tablet (clinical drug)27/07/2020
Product containing precisely bisacodyl 2 milligram/ 1 millilitre conventional release rectal suspension (clinical drug)27/07/2020
Product containing precisely phenazone 50 milligram/1 millilitreeach conventional release solution for ear drops (clinical drug)


Product containing precisely ceritinib 150 milligram/1 each conventional release oral tablet (clinical drug)08/09/2020
Product containing idelalisib in oral dose form (medicinal product form)08/09/2020
Product containing only idelalisib in oral dose form (medicinal product form)08/09/2020
Product containing precisely ipilimumab 5 milligram/1 milliliter conventional release solution for infusion (clinical drug)08/09/2020
Product containing precisely bortezomib 3.5 milligram/1 vial powder for conventional release solution for injection (clinical drug)08/09/2020
Product containing arsenic trioxide in parenteral dose form (medicinal product form)08/09/2020
Product containing only arsenic trioxide in parenteral dose form (medicinal product form)
At risk of human trafficking (finding)08/09/2020
Has child subject of child protection plan (situation)08/09/2020
Frequent attender of accident and emergency department (finding)08/09/2020
Family history of alcohol misuse (situation)08/09/2020
Adult safeguarding concern (finding)08/09/2020
Family is cause for concern (finding)08/09/2020
Carer behaviour is cause for safeguarding concern (situation)08/09/2020
Unborn child is cause for safeguarding concern (finding)08/09/2020
No safeguarding issues identified (finding)
At risk of financial abuse (finding)08/09/2020
At risk of forced marriage (finding)08/09/2020
At risk of institutional abuse (finding)08/09/2020
Domestic abuse victim in household (finding)08/09/2020
Alleged victim of sexual assault (situation)




Approvals


Final Version

Date

Approver

Comments

0.1


Terance Shird


1.0

 

Theresa BarryApproved



Download .pdf here:







Draft Amendment History


Version

Date

Editor

Comments

0.1

 

Andrew AtkinsonInitial draft created
1.0

 

Theresa BarryFinal draft


  • No labels